Seeking Alpha

Halozyme Therapeutics (HALO +4.4%) moves up after saying results from a Phase 2 study of...

Halozyme Therapeutics (HALO +4.4%) moves up after saying results from a Phase 2 study of rHuPH20, a prandial insulin, met its primary endpoint for blood sugar measurement in patients with Type 1 diabetes. Additionally, data from the study further indicated that rHuPH20 also reduced postprandial glycemic excursions, as well as significantly reduced hypoglycemic events.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|